An agreed PIP is the regulatory pathway to market authorization for leniolisib as a treatment of activated phosphoinositide 3-kinase delta syndrome in children Leiden, The Netherlands, 06 January, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results